Overview of European pilot study of interferon beta-Ib in primary progressive multiple sclerosis.
This short monograph describes a trial of interferon beta-1b in patients with primary progressive multiple sclerosis (PPMS) or transitional MS. Designed as a randomized, placebo-controlled pilot, the trial randomly placed 73 eligible patients into two groups, placebo or interferon beta-1b 8 MIU given subcutaneously every other day for two years. Significant differences favouring interferon beta-1b in the MSFC score, T2 lesion volume and TI lesion volume at 24 months were observed. Further study of interferon beta-Ib therapy in PPMS patients in warranted.
Montalban
Xavier
X
University Hospital Vall d'Hebron, Unitat de Neuroimmunologia Clinica, Pg Val d'Hebron 119-129 (EUI-2a P.) E-08035, Barcelona, Spain. xmontalban@.vhebron.net
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D005060:Europe; D006801:Humans; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use*; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy*; D010865:Pilot Projects
D000276:Adjuvants, Immunologic; D000068576:Interferon beta-1b; D016899:Interferon-beta